Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 7, 2025Theoretical and Natural Science

The Evolving Landscape of Immunotherapy in Triple-negative Breast Cancer: Mechanisms, Biomarkers, and Future Horizons

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJun Lyu

Discussion

Loading...

Member takes

Overview

Review synthesizes recent insights on immunotherapy efficacy and biomarkers in triple-negative breast cancer, highlighting significant progress.

Key Points

  • Triple-negative breast cancer is an aggressive form of cancer with limited treatment options historically.
  • Recent studies show that immune checkpoint inhibitors improve overall survival in early-stage triple-negative breast cancer.
  • Antibody-drug conjugates like sacituzumab govitecan are now standard for treating metastatic triple-negative breast cancer.
  • Emerging biomarkers such as TILs are vital for predicting treatment responses and shaping personalized therapies.

Cite This Study

Jun Lyu (2025) studied this question.

synapsesocial.com/papers/689522189f4f1c896c429f08https://doi.org/10.54254/2753-8818/2025.ld25832
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Immunotherapy innovations in triple-negative breast cancer: targeting checkpoints, combinations, and biomarkers2026 · 1 citations
  2. 2Present and Future of Immunotherapy for Triple-Negative Breast Cancer2024 · 6 citations
  3. 3Immunotherapy Approaches for the Treatment of Triple-Negative Breast Cancer2026 · 5 citations
  4. 4Advancements in Immune Checkpoint-Based Immunotherapy for Triple-Negative Breast Cancer2026
  5. 5Integrating molecular targeting and immune modulation in triple-negative breast cancer: from mechanistic insights to therapeutic innovation2025 · 5 citations